Teligent, Inc. (NASDAQ:TLGT) Director Carole Ben-Maimon purchased 5,000 shares of the stock in a transaction dated Monday, November 13th. The shares were acquired at an average cost of $3.48 per share, with a total value of $17,400.00. Following the acquisition, the director now directly owns 2,400 shares in the company, valued at approximately $8,352. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Teligent, Inc. (TLGT) opened at $3.48 on Tuesday. Teligent, Inc. has a fifty-two week low of $2.82 and a fifty-two week high of $9.54. The company has a quick ratio of 3.71, a current ratio of 4.37 and a debt-to-equity ratio of 1.99.
Teligent (NASDAQ:TLGT) last issued its earnings results on Monday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.07). Teligent had a negative return on equity of 6.38% and a negative net margin of 16.95%. The firm had revenue of $13.65 million during the quarter, compared to analyst estimates of $19.12 million. During the same period in the previous year, the company earned $0.01 EPS. Teligent’s revenue for the quarter was down 15.5% on a year-over-year basis. analysts anticipate that Teligent, Inc. will post -0.13 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This report was originally published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.thestockobserver.com/2017/11/14/teligent-inc-tlgt-director-carole-ben-maimon-purchases-5000-shares-of-stock.html.
A number of brokerages have issued reports on TLGT. Zacks Investment Research cut Teligent from a “hold” rating to a “strong sell” rating in a report on Saturday. Canaccord Genuity reaffirmed a “buy” rating and issued a $11.00 target price on shares of Teligent in a report on Tuesday, August 8th. Roth Capital set a $9.00 target price on Teligent and gave the stock a “buy” rating in a report on Wednesday, August 23rd. BidaskClub cut Teligent from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Finally, Deutsche Bank AG reaffirmed a “hold” rating and issued a $9.00 target price (up previously from $8.00) on shares of Teligent in a report on Monday, July 17th. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company. Teligent currently has a consensus rating of “Hold” and a consensus price target of $7.33.
Several hedge funds have recently modified their holdings of the company. Rhumbline Advisers increased its stake in shares of Teligent by 0.4% in the second quarter. Rhumbline Advisers now owns 49,622 shares of the company’s stock valued at $454,000 after buying an additional 200 shares during the period. Wells Fargo & Company MN increased its stake in shares of Teligent by 3.1% in the first quarter. Wells Fargo & Company MN now owns 45,617 shares of the company’s stock valued at $357,000 after buying an additional 1,369 shares during the period. American International Group Inc. increased its stake in shares of Teligent by 7.1% in the first quarter. American International Group Inc. now owns 25,488 shares of the company’s stock valued at $199,000 after buying an additional 1,680 shares during the period. Voya Investment Management LLC increased its stake in shares of Teligent by 16.1% in the second quarter. Voya Investment Management LLC now owns 23,342 shares of the company’s stock valued at $214,000 after buying an additional 3,234 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of Teligent by 9.1% in the first quarter. Bank of America Corp DE now owns 39,458 shares of the company’s stock valued at $307,000 after buying an additional 3,293 shares during the period. 65.85% of the stock is owned by institutional investors.
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
Receive News & Ratings for Teligent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent Inc. and related companies with MarketBeat.com's FREE daily email newsletter.